Mucosal prior to systemic application of recombinant adenovirus boosting is more immunogenic than systemic application twice but confers similar protection against SIV-challenge in DNA vaccine-primed macaques. (Q51960480)

From Wikidata

Jump to navigation Jump to search

scientific article published on 21 November 2008

Language	Label	Description	Also known as
English	Mucosal prior to systemic application of recombinant adenovirus boosting is more immunogenic than systemic application twice but confers similar protection against SIV-challenge in DNA vaccine-primed macaques.	scientific article published on 21 November 2008

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19027133%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Mucosal prior to systemic application of recombinant adenovirus boosting is more immunogenic than systemic application twice but confers similar protection against SIV-challenge in DNA vaccine-primed macaques (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19027133%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference

based on heuristic

inferred from title

Sieghart Sopper

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19027133%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Christiane Stahl-Hennig

12

object named as

Christiane Stahl-Hennig

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19027133%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

author name string

Reiner Schulte

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19027133%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

You-Suk Suh

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19027133%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Ulrike Sauermann

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19027133%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Washingtone Ochieng

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19027133%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Kwang S Kim

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19027133%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

So-Shin Ahn

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19027133%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Ki S Park

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19027133%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Nicole Stolte-Leeb

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19027133%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Gerhard Hunsmann

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19027133%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Young C Sung

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19027133%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

language of work or name

0 references

publication date

21 November 2008

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19027133%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19027133%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

383

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19027133%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

300-309

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19027133%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19027133%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.012

7 January 2021

Protection against simian/human immunodeficiency virus (SHIV) 89.6P in macaques after coimmunization with SHIV antigen and IL-15 plasmid

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.012

7 January 2021

Comparative Immunogenicity in Rhesus Monkeys of DNA Plasmid, Recombinant Vaccinia Virus, and Replication-Defective Adenovirus Vectors Expressing a Human Immunodeficiency Virus Type 1 gag Gene

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.012

7 January 2021

Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.012

7 January 2021

Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.012

7 January 2021

Characterization of a CD4-expressing macaque cell line that can detect virus after a single replication cycle and can be infected by diverse simian immunodeficiency virus isolates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.012

7 January 2021

Oral priming of mice by recombinant spores of Bacillus subtilis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.012

7 January 2021

Comparative efficacy of subtype AE simian-human immunodeficiency virus priming and boosting vaccines in pigtail macaques.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.012

7 January 2021

Sequential priming with simian immunodeficiency virus (SIV) DNA vaccines, with or without encoded cytokines, and a replicating adenovirus-SIV recombinant followed by protein boosting does not control a pathogenic SIVmac251 mucosal challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.012

7 January 2021

Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.012

7 January 2021

Replication-defective vector based on a chimpanzee adenovirus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.012

7 January 2021

Cytokine expression, natural killer cell activation, and phenotypic changes in lymphoid cells from rhesus macaques during acute infection with pathogenic simian immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.012

7 January 2021

Therapeutic vaccination with simian immunodeficiency virus (SIV)-DNA + IL-12 or IL-15 induces distinct CD8 memory subsets in SIV-infected macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.012

7 January 2021

Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.012

7 January 2021

Improved vaccine protection from simian AIDS by the addition of nonstructural simian immunodeficiency virus genes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.012

7 January 2021

Interleukin-15 but not interleukin-7 abrogates vaccine-induced decrease in virus level in simian immunodeficiency virus mac251-infected macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.012

7 January 2021

Mucosal priming with replicative Tiantan vaccinia and systemic boosting with DNA vaccine raised strong mucosal and systemic HIV-specific immune responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.012

7 January 2021

Mucosal priming with PEI/DNA complex and systemic boosting with recombinant TianTan vaccinia stimulate vigorous mucosal and systemic immune responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.012

7 January 2021

Vaccine protection from CD4+ T-cell loss caused by simian immunodeficiency virus (SIV) mac251 is afforded by sequential immunization with three unrelated vaccine vectors encoding multiple SIV antigens.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.012

7 January 2021

Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.012

7 January 2021

Immunogenicity and efficacy of immunodeficiency virus-like particles pseudotyped with the G protein of vesicular stomatitis virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.012

7 January 2021

The synthetic peptide Trp-Lys-Tyr-Met-Val-D-Met as a novel adjuvant for DNA vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.012

7 January 2021

Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.012

7 January 2021

Enhanced cellular immunity and systemic control of SHIV infection by combined parenteral and mucosal administration of a DNA prime MVA boost vaccine regimen.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.012

7 January 2021

A replication competent adenovirus 5 host range mutant-simian immunodeficiency virus (SIV) recombinant priming/subunit protein boosting vaccine regimen induces broad, persistent SIV-specific cellular immunity to dominant and subdominant epitopes in M

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.012

7 January 2021

Durable protection of rhesus macaques immunized with a replicating adenovirus-SIV multigene prime/protein boost vaccine regimen against a second SIVmac251 rectal challenge: role of SIV-specific CD8+ T cell responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.012

7 January 2021

Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.012

7 January 2021

Vaccination preserves CD4 memory T cells during acute simian immunodeficiency virus challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.012

7 January 2021

Adenovirus-based prime-boost immunization for rapid vaccination against anthrax

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.012

7 January 2021

Rabies virus-based vectors expressing human immunodeficiency virus type 1 (HIV-1) envelope protein induce a strong, cross-reactive cytotoxic T-lymphocyte response against envelope proteins from different HIV-1 isolates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.012

7 January 2021

Enhanced humoral HIV-1-specific immune responses generated from recombinant rhabdoviral-based vaccine vectors co-expressing HIV-1 proteins and IL-2.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.012

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.012

7 January 2021

T-cell-mediated protective efficacy of a systemic vaccine approach in cynomolgus monkeys after SIV mucosal challenge.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.012

7 January 2021

Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.012

7 January 2021

MHC class I alleles influence set-point viral load and survival time in simian immunodeficiency virus-infected rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.012

7 January 2021

IL-15 treatment during acute simian immunodeficiency virus (SIV) infection increases viral set point and accelerates disease progression despite the induction of stronger SIV-specific CD8+ T cell responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.012

7 January 2021

Protective efficacy of a multicomponent vector vaccine in cynomolgus monkeys after intrarectal simian immunodeficiency virus challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.012

7 January 2021

Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.012

7 January 2021

Development and homeostasis of T cell memory in rhesus macaque

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.012

7 January 2021

IL-15 induces CD4 effector memory T cell production and tissue emigration in nonhuman primates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.012

7 January 2021

Mhc class I haplotypes associated with survival time in simian immunodeficiency virus (SIV)-infected rhesus macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.012

7 January 2021

The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.012

7 January 2021

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.012

7 January 2021

Lymphocyte subsets and expression of differentiation markers in blood and lymphoid organs of rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.012

7 January 2021

Enhanced cellular immune response and reduced CD8(+) lymphocyte apoptosis in acutely SIV-infected Rhesus macaques after short-term antiretroviral treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.012

7 January 2021

Rapid infection of oral mucosal-associated lymphoid tissue with simian immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.012

7 January 2021

Atraumatic oral spray immunization with replication-deficient viral vector vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.012

7 January 2021

Immunogenicity of a DNA prime and recombinant adenovirus boost regime significantly varies between rhesus macaques of Chinese and Indian origins.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.012

7 January 2021

Better Protective Effects in Rhesus Macaques by Combining Systemic and Mucosal Application of a Dual Component Vector Vaccine After Rectal SHIV89.6P Challenge Compared to Systemic Vaccination Alone

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.012

7 January 2021

Reduction of viral loads by multigenic DNA priming and adenovirus boosting in the SIVmac-macaque model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.012

7 January 2021

Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.012

7 January 2021

Immunogenicity of heterologous recombinant adenovirus prime-boost vaccine regimens is enhanced by circumventing vector cross-reactivity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.012

7 January 2021

Mucosal application of plasmid-encoded IL-15 sustains a highly protective anti-Herpes simplex virus immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.012

7 January 2021

Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.012

7 January 2021

Evaluation of oral tenofovir disoproxil fumarate and topical tenofovir GS-7340 to protect infant macaques against repeated oral challenges with virulent simian immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.012

7 January 2021

The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.012

7 January 2021

Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.012

7 January 2021

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51960480&oldid=1369532956"